What’s new in treating hepatocellular carcinoma, the most …
Apr 14, 2023 · Hepatocellular carcinoma, the most common type of liver cancer, has historically been difficult to treat since most people diagnosed with the disease have existing liver disease. But thanks to new research, there’s good news for hepatocellular carcinoma treatment, says Ahmed Kaseb, M.D.
Hepatocellular carcinoma - Latest research and news - Nature
Dec 28, 2024 · Hepatocellular carcinoma (HCC) accounts for approximately 80% of all cases of primary liver cancer, the third leading cause of cancer mortality worldwide. In this Review, the authors...
Coherus to Present Final Phase 2 Casdozokitug Combination Data …
Dec 18, 2024 · Hepatobiliary cancers include a spectrum of invasive carcinomas arising in the liver (hepatocellular carcinoma; HCC), gall bladder, and bile ducts (collectively called biliary tract cancers).
QXL-138AM by Nammi Therapeutics for Metastatic Hepatocellular Carcinoma …
According to GlobalData, Phase I drugs for Metastatic Hepatocellular Carcinoma (HCC) have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how QXL-138AM’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
Hepatocellular Carcinoma - latest research news and features
Hepatocellular carcinoma, a type of liver cancer, is the sixth most common cancer worldwide and the third leading cause of cancer-related deaths. Screening efforts for this cancer focus on...
Muzastotug by Adagene Suzhou for Hepatocellular Carcinoma: …
According to GlobalData, Phase II drugs for Hepatocellular Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Muzastotug’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
TCR sequencing sheds light on tumor immune interactions in ...
Dec 11, 2024 · Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally. Often diagnosed at advanced stages, the...
Drug Development in Hepatocellular Carcinoma ... - ASCO Daily News
Jan 5, 2023 · The past decade has seen substantial progress in drug development in hepatocellular carcinoma (HCC), with the standard of care shifting from sorafenib to atezolizumab plus bevacizumab during an explosion of immunotherapeutic research.
Investigating fatty acid metabolism in hepatocellular carcinoma …
6 days ago · Guo, Y., et al. (2024). Bioinformatics-based analysis of fatty acid metabolic reprogramming in hepatocellular carcinoma: cellular heterogeneity, therapeutic targets, and drug discovery.
Hepatocellular Carcinoma: New Developments - PubMed
This is a review of current practices and upcoming developments regarding hepatocellular carcinoma (HCC). This includes a contemporary review of the diagnosis, staging, and treatment of HCC. Furthermore, the authors provide a review of certain ongoing trials and future directions of various treatmen …